MAIA Biotechnology, Inc. (MAIA) Stock Score, Valuation & Financial Research

MAIA Biotechnology, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MAIA

MAIA Biotechnology, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.20. These figures are a research snapshot, not a buy or sell recommendation.

What MAIA Biotechnology, Inc. does

MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

MAIA Biotechnology is a clinical-stage biopharmaceutical company focused on the development and commercialization of targeted immuno-oncology therapies. As a development-stage entity, the company does not currently generate revenue from product sales and relies on capital raises to fund its research, clinical trials, and operational expenses.

Products and services

  • The company's primary product candidate is THIO (6-thio-2'-deoxyguanosine), a telomere-targeting agent currently in clinical development for the treatment of various cancers.

Brands and product families

  • THIO — Lead telomere-targeting drug candidate. Source

Customer types

Healthcare providers and patients (future potential).

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) — The company engages various third-party CROs to manage and conduct its clinical trials and pre-clinical research activities. Source

Business strengths to evaluate

  • Proprietary telomere-targeting technology platform Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MAIA financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.20
Market capitalization:
72.96M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -26.85M
Free cash flow:
USD -18.84M
Cash:
USD 27.6M
Total debt:
USD 0.00
EPS:
USD -0.63

What stands out

  • Free cash flow is USD -18.84M, negative for the stored period.
  • The balance sheet shows USD 27.6M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 27.6M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MAIA

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MAIA fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MAIA likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MAIA to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of MAIA's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research MAIA

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.